Cationic liposomal vaccine adjuvants in animal challenge models: overview and current clinical status

Expert Rev Vaccines. 2012 May;11(5):561-77. doi: 10.1586/erv.12.22.

Abstract

Cationic liposome formulations can function as efficient vaccine adjuvants. However, due to the highly diverse nature of lipids, cationic liposomes have different physical-chemical characteristics that influence their adjuvant mechanisms and their relevance for use in different vaccines. These characteristics can be further manipulated by incorporation of additional lipids or stabilizers, and inclusion of carefully selected immunostimulators is a feasible strategy when tailoring cationic liposomal adjuvants for specific disease targets. Thus, cationic liposomes present a plasticity, which makes them promising adjuvants for future vaccines. This versatility has also led to a vast amount of literature on different experimental liposomal formulations in combination with a wide range of immunostimulators. Here, we have compiled information about the animal challenge models and administration routes that have been used to study vaccine adjuvants based on cationic liposomes and provide an overview of the applicability, progress and clinical status of cationic liposomal vaccine adjuvants.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adjuvants, Immunologic* / administration & dosage
  • Adjuvants, Immunologic* / chemistry
  • Animals
  • Clinical Trials as Topic
  • Disease Models, Animal
  • Drug Delivery Systems
  • Guinea Pigs
  • Humans
  • Liposomes / chemistry
  • Liposomes / immunology*
  • Mice
  • Rats
  • Vaccines / administration & dosage*

Substances

  • Adjuvants, Immunologic
  • Liposomes
  • Vaccines